Cargando…

PB1796: DETERMINATION OF THE RELATIONSHIP BETWEEN NEXT GENERATION SEQUENCING AND FLOW CYTOMETRY RESULTS IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA

Detalles Bibliográficos
Autores principales:	Yavasoglu, I., küçükdiler, A. H. E., erdoğdu, I., bolaman, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430813/ http://dx.doi.org/10.1097/01.HS9.0000850036.44279.df

Ejemplares similares

PB1781: THERAPEUTIC POTENTIAL OF DNA DAMAGE RESPONSE IN ACUTE MYELOBLASTIC LEUKEMIA
por: Lapa, B., et al.
Publicado: (2022)

PB1868: COMPARISON OF MYELOBLAST CELL PERCENTAGE IN INVESTIGATIONS FOR ACUTE MYELOID LEUKAEMIA INCLUDING FLOW CYTOMETRY, BONE MARROW ASPIRATION AND BONE MARROW TREPHINE
por: Iftikhar, Naml
Publicado: (2023)

PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
por: Pereira, Marta, et al.
Publicado: (2023)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

PB1839: CYTOGENETIC PROFILE OF ACUTE MYELOBLASTIC LEUKEMIA TREATED AT THE MOHAMMED V MILITARY HOSPITAL IN RABAT (MOROCCO).
por: Hawa, Moussa Bouh, et al.
Publicado: (2023)

PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
por: Lapa, Beatriz, et al.
Publicado: (2023)

PB1907: EPIDEMIOLOGICAL PROFILE AND DIAGNOSTIC FEATURES OF ACUTE MYELOBLASTIC LEUKEMIA IN ADULTS: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Siala, Nour, et al.
Publicado: (2023)

PB1741: DIFFERENTIAL DIAGNOSIS OF T-LYMPHOBLASTIC LYMPHOMA/LEUKEMIA AND THYMOMA USING FLOW CYTOMETRY IN PLEURAL FLUID
por: Bae, Goeun, et al.
Publicado: (2023)

PB1796: ADMINISTRATION OF A KETOGENIC DIET FOR CHEMOTHERAPY PROTECTION IN ACUTE LEUKEMIA PATIENTS: IS IT FEASIBLE, SAFE, AND VALUABLE? PRELIMINARY RESULTS OF THE RANDOMIZED CONTROLLED TRIAL LEU-KETO STUDY.
por: Cagigas, Maria Lastra, et al.
Publicado: (2023)

PB1752: SAMATYA-PREDICTING SCORE IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): COMBINING CLINICAL FEATURES WITH FLOW CYTOMETRY
por: Cinli, Tahir Alper, et al.
Publicado: (2023)

PB1839: INDEPENDENT PROGNOSTIC VALUE OF A PLATELET COUNT OVER 300X109/L IN ACUTE MYELOBLASTIC LEUKEMIA PATIENTS TREATED WITH AN INTENSIVE REGIMEN.
por: Ródenas Quiñonero, I., et al.
Publicado: (2022)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
por: Park, Young Seob, et al.
Publicado: (2023)

PB1837: ADDITION OF A THIRD, NON-TARGETED, AGENT TO CYTARABINE- AND ANTHRACYCLINE-BASED INDUCTION CHEMOTHERAPY FOR ACUTE MYELOBLASTIC LEUKEMIA INCREASES COMPLETE REMISSIONS AND TREATMENT-RELATED MORTALITY
por: Pereira, M., et al.
Publicado: (2022)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

PB1954: PROGNOSTIC ANALYSIS OF GENE MUTATIONS ON TIME-TO-FIRST TREATMEN IN 93 NEWLY DIAGNOSED CHRONIC LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Xiang, Xixi, et al.
Publicado: (2023)

PB1710: AN EXTENDED FLOW CYTOMETRY PANEL AS A SCREENING TOOL FOR PH-LIKE ALL
por: Cieloch, Adrianna, et al.
Publicado: (2023)

PB2009: OPPORTUNITIES OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Kliuchagina, I., et al.
Publicado: (2022)

PB2577: INFECTIONS AND THEIR RELATIONSHIP WITH EARLY MORTALITY IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
por: Ontiveros-Austria, Juan Luis, et al.
Publicado: (2023)

PB2206: FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: chen, M., et al.
Publicado: (2022)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB2017: YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A TUNISIAN SINGLE-CENTER EXPERIENCE
por: Kallel, F., et al.
Publicado: (2022)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB2298: THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB2358: SIGNIFICANT INCREASE IN NEWLY DIAGNOSED HEMATOLOGICAL MALIGNANCIES FOLLOWING LOCKDOWN EASE IN CROATIA
por: Simunic, M., et al.
Publicado: (2022)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB1777: DEVELOPMENT OF NEXT GENERATION SEQUENCING PANELS FOR SCREENING FUSION GENES IN LEUKEMIA
por: Çiğdem, S., et al.
Publicado: (2022)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

PB2088: IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE
por: Rivero Arango, A., et al.
Publicado: (2022)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB2175: TRYPAN BLUE AND FLOW CYTOMETRY CELL VIABILITY TESTING OF PACKED OR DILUTED CRYOPRESERVED AT -80ºC HEMATOPOIETIC STEM CELLS SHOW SIMILAR RESULTS
por: Tonev, I., et al.
Publicado: (2022)

PB2153: SURGICAL SPECIMENS OF INDOLENT AND AGGRESSIVE B-NHLS SHOW DIFFERENCES IN THEIR FLOW-CYTOMETRY PROFILE OF PLOIDY, PROLIFERATING FRACTION AND PROPORTION OF TUMOR-ASSOCIATED MYELOID AND T-CELL SUBSETS
por: Azoulay, D., et al.
Publicado: (2022)

PB2495: QUANTIFICATION AND IMMUNOPHENOTYPIC CHARACTERISATION OF CAR T-CELLS BY FLOW CYTOMETRY AND CORRELATION WITH CLINICAL OUTCOMES FOR PATIENTS WITH LARGE B CELL LYMPHOMA
por: Wayte, Rebecca, et al.
Publicado: (2023)

PB1769: REAL WORLD DATA OUTCOMES IN A SINGLE MEXICAN PUBLIC INSTITUTION. ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH NEWLY DIAGNOSED OF ACUTE LYMPHOBLASTIC LEUKEMIA:COMPARATIVE RESULTS OF DIFFERENT PROTOCOLS
por: Sotomayor Duque, G., et al.
Publicado: (2022)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fgiovr6l3f5k7r2kjbsh526cle